Results 121 to 130 of about 6,610 (157)
Some of the next articles are maybe not open access.
Experiences with Recombinant Factor VIIa in Hemophiliacs
1991Treatment of hemophiliacs with antibodies against factor VIII and factor IX is a matter of major concern in hemophilia care. Although a number of sophisticated methods for removal of antibodies have been designed, such procedures are suitable only in life-threatening situations since they are complicated and expensive.1, 2 Much effort has been focused ...
openaire +2 more sources
Recombinant factor VIIa and the surgical patient
Current Opinion in Critical Care, 2006Bleeding remains a challenge in surgery. A unique drug, recombinant factor VIIa, causes clotting exclusively at bleeding sites. Recombinant factor VIIa has recently been introduced to surgery where current evidence, consisting mostly of case reports, suggest remarkable safety and efficacy.
Sandro, Scarpelini, Sandro, Rizoli
openaire +2 more sources
Recombinant factor VIIa: safety and efficacy
Current Opinion in Hematology, 2007Recombinant factor VIIa has been increasingly used to provide hemostasis in nonapproved indications. This trend has resulted in concerns about safety, efficacy and costs.Recombinant factor VIIa seems to have hemostatic effects in posttrauma and perisurgery excessive bleeding, although further studies are required. Recombinant factor VIIa may be used to
Lawrence T, Goodnough, Aryeh S, Shander
openaire +2 more sources
AACN Advanced Critical Care, 2007
Uncontrolled bleeding and coagulopathy are associated with trauma, liver failure, obstetric conditions, and a variety of surgical circumstances, resulting in increased morbidity and mortality in the critically ill. Recently, the role of recombinant factor VIIa (rFVIIa) in the management of uncontrolled bleeding has attracted interest.
openaire +1 more source
Uncontrolled bleeding and coagulopathy are associated with trauma, liver failure, obstetric conditions, and a variety of surgical circumstances, resulting in increased morbidity and mortality in the critically ill. Recently, the role of recombinant factor VIIa (rFVIIa) in the management of uncontrolled bleeding has attracted interest.
openaire +1 more source
Clinical experience with recombinant factor VIIa
Blood Coagulation & Fibrinolysis, 1998Recombinant factor VIIa (rFVIIa) represents a major therapeutic advance in the treatment of haemophilia patients with inhibitors. The efficacy and safety of rFVIIa has been extensively studied in over 1900 surgical and non-surgical bleeding episodes in over 400 patients with haemophilia A or B (with or without inhibitors) or acquired haemophilia.
J, Lusher +3 more
openaire +2 more sources
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa
Clinical Pharmacology and Therapeutics, 1994To evaluate the pharmacokinetics and pharmacodynamics of recombinant activated factor VII (rFVIIa).Single-dose pharmacokinetics of three dose levels (17.5, 35, and 70 micrograms/kg) of rFVIIa were investigated in 15 patients with hemophilia with severe factor VIII or factor IX deficiency (with or without inhibitors) while they were in the nonbleeding ...
C M, Lindley +8 more
openaire +2 more sources
Safety profile of recombinant factor VIIa
Seminars in Hematology, 2004Recombinant factor VIIa (rFVIIa; NovoSeven(R), Novo Nordisk, Bagsvaerd, Denmark) has been used for many years in the successful management of bleeding episodes in patients with hemophilia and inhibitors. More recently, rFVIIa has also shown considerable success as a hemostatic agent in trauma and surgery patients without pre-existing coagulopathy ...
Harold R, Roberts +2 more
openaire +2 more sources
Uses of recombinant factor VIIa in trauma
Current Opinion in Critical Care, 2004Despite advances in the care of the injured, the morbidity and mortality of traumatic hemorrhage remain a significant problem. Traumatologists continue to look for ways to treat bleeding and prevent the sequelae of hemorrhagic shock. Recombinant factor VIIa, developed for the treatment of patients with hemophilia, has been used with some success in ...
Deborah M, Stein, Richard P, Dutton
openaire +2 more sources
Antidotes to haemorrhage: recombinant factor VIIa
Best Practice & Research Clinical Haematology, 2004Recombinant Factor VIIa (rFVIIa) concentrates were originally developed to treat the refractory bleeding complications associated with allo-antibody inhibitors in hemophilias A and B. As experience was gained in the hemophilias, the physiology of rFVIIa and its successes in controlling bleeds stimulated rFVIIa use in other challenging medical ...
openaire +2 more sources